Payment overview · 2025
General Payments
$138.42
7 reported records · 4 companies
Healthcare provider profile · identity verified
Jitinder Singh, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEW LENOX, IL · NPI 1194812602
Verified facts
What the public records show
CMS Open Payments records show Jitinder Singh, D.O. received $138.42 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 49.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.40 | 49.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.82 | 21.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.30 | 14.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.90 | 14.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $138.42 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.47 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| Bulkamid - Bulkamid Urethral Bulking Pack 2mL (OUS) Normalized: bulkamid bulkamid urethral bulking pack 2ml ous |
Device | Boston Scientific Corporation | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1067 | 306 |
| Levothyroxine Sodium | Levothyroxine Sodium | 632 | 162 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 123 |
| Alprazolam | Alprazolam | 386 | 103 |
| Omeprazole | Omeprazole | 384 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 98 |
| Azithromycin | Azithromycin | 337 | 240 |
| Lisinopril | Lisinopril | 326 | 95 |
| Metformin Hcl | Metformin Hcl | 278 | 80 |
| Glimepiride | Glimepiride | 257 | 78 |
| Losartan Potassium | Losartan Potassium | 257 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 236 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 67 |
| Simvastatin | Simvastatin | 227 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 66 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 51 |
| Tramadol Hcl | Tramadol Hcl | 158 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 158 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 40 |
| Metformin Hcl Er | Metformin Hcl | 142 | 47 |
| Methylprednisolone | Methylprednisolone | 140 | 123 |
| Zolpidem Tartrate | Zolpidem Tartrate | 138 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 131 | 37 |
| Ezetimibe | Ezetimibe | 124 | 40 |
| Meloxicam | Meloxicam | 123 | 31 |
| Glipizide | Glipizide | 121 | 33 |
| Montelukast Sodium | Montelukast Sodium | 113 | 30 |
| Allopurinol | Allopurinol | 104 | 32 |
| Gabapentin | Gabapentin | 100 | 42 |
| Sertraline Hcl | Sertraline Hcl | 99 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 32 |
| Mounjaro | Tirzepatide | 87 | 17 |
| Furosemide | Furosemide | 82 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 20 |
| Famotidine | Famotidine | 79 | 27 |
| Eliquis | Apixaban | 76 | 25 |
| Januvia | Sitagliptin Phosphate | 76 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 20 |
| Prednisone | Prednisone | 72 | 56 |
| Valsartan | Valsartan | 70 | 23 |
| Lorazepam | Lorazepam | 67 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 51 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 46 |
| Trazodone Hcl | Trazodone Hcl | 65 | 14 |
| Farxiga | Dapagliflozin Propanediol | 64 | 16 |
| Meclizine Hcl | Meclizine Hcl | 60 | 24 |
| Temazepam | Temazepam | 60 | 11 |
| Carvedilol | Carvedilol | 59 | 17 |
| Synthroid | Levothyroxine Sodium | 58 | 18 |
| Potassium Chloride | Potassium Chloride | 57 | 20 |
| Levoxyl | Levothyroxine Sodium | 54 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 18 |
| Jardiance | Empagliflozin | 52 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 20 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Atenolol | Atenolol | 47 | 13 |
| Celecoxib | Celecoxib | 47 | 19 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 46 | 14 |
| Ozempic | Semaglutide | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 14 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 26 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 18 |
| Valacyclovir | Valacyclovir Hcl | 29 | 20 |
| Levofloxacin | Levofloxacin | 28 | 24 |
| Propranolol Hcl | Propranolol Hcl | 28 | 11 |
| Amoxicillin | Amoxicillin | 27 | 23 |
| Ramipril | Ramipril | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $138.42 · 7 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Bulkamid - Bulkamid Urethral Bulking Pack 2mL (OUS), Ozempic, QULIPTA, Rybelsus, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error